Entering text into the input field will update the search result below

AstraZeneca's selumetinib an Orphan Drug for eye cancer

Apr. 17, 2015 7:09 AM ETAstraZeneca PLC (AZN) StockAZNBy: Douglas W. House, SA News Editor
  • The FDA designates AstraZeneca's (NYSE:AZN) selumetinib an Orphan Drug for the treatment of uveal melanoma, a rare disease in which cancer cells form in the tissues of the eye. It is the most common primary intraocular malignancy in adults. The incidence is 4.3 cases per 1M people and peaks near the age of 70.
  • Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

Recommended For You

More Trending News

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC